Study Title

A Phase I Trial to Determine the Maximum Tolerated Dose and Patient-specific Dosimetry of Fractionated Intracavitary Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment

Study Details

Description:

Locoregional, intracavitary radioimmunotherapy (iRIT) with a newly developed radioimmunoconjugate (Lu-177 labeled 6A10-Fab-fragments) will be used to prevent or postpone tumour recurrence in patients with GBM following standard therapy .

Sponsor:

University Hospital Muenster

Government Study Link:

NCT05533242 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468